Innovation1 Biotech Inc. (IVBT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInnovation1 Biotech Inc. (IVBT) trades at $0.0002. Innovation1 Biotech Inc. is a biotechnology company focused on drug discovery, particularly in developing modified botanical Schedule 1 molecules. Sector: Financials.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for IVBT: IVBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Innovation1 Biotech Inc. (IVBT) Financial Services Profile
Innovation1 Biotech Inc. specializes in drug discovery with a focus on synthetic prodrugs derived from botanical sources, addressing unmet medical needs in mental health and pediatric conditions.
What Is the Investment Thesis for IVBT?
Innovation1 Biotech Inc. is positioned for growth through its innovative pipeline of synthetic prodrugs targeting significant medical conditions. The company’s focus on psychedelic compounds and cannabinoids aligns with emerging trends in mental health treatment and chronic conditions, potentially offering substantial market opportunities. As the firm progresses its five prodrugs through preclinical development, successful advancements could lead to partnerships or funding opportunities that enhance its financial stability. The current lack of competition in its specific therapeutic areas, such as pediatric epilepsy and addiction treatment, further strengthens its market position. However, the company faces risks associated with regulatory hurdles and the inherent uncertainties of drug development timelines, which could impact its ability to bring products to market within anticipated timeframes.
Based on FMP financials and quantitative analysis
IVBT Key Highlights
Market Cap: $0.00B, indicating a nascent stage in its market presence.
- Beta: 5.83, reflecting high volatility compared to the market.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Pipeline includes five proprietary prodrugs in preclinical development, targeting unique medical conditions.
- Established in 2014, with a rebranding to Innovation1 Biotech Inc. in March 2022.
Who Are IVBT's Competitors?
IVBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CMPS COMPASS Pathways plc | $8.65 | +6.53% | $1.23B | — |
| AXSM Axsome Therapeutics, Inc. | $135.68 | +1.25% | $7.14B | 34 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.20 | -0.20% | $23.8M | 43 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $6.48 | -24.74% | $26.9M | 47 5-pillar |
| AFJK Aimei Health Technology Co., Ltd | $11.90 | +0.76% | $37.7M | 43 5-pillar |
| AIB AIB Acquisition Corporation | $0.63 | -3.82% | $48.5M | 30 5-pillar |
| PGAC Pantages Capital Acquisition Corporation | $10.87 | -0.09% | $55.8M | 55 5-pillar |
| CHAR Charlton Aria Acquisition Corporation | $10.99 | +0.32% | $57.6M | 46 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVBT's Key Strengths?
Innovative pipeline of synthetic prodrugs addressing significant medical needs.
- Established expertise in drug discovery and development.
- Strong focus on mental health and pediatric conditions, which are gaining attention.
What Are IVBT's Weaknesses?
Limited resources with only one employee, impacting operational capacity.
- High volatility and risk associated with early-stage biotechnology companies.
- Lack of established revenue streams due to preclinical status.
What Are the Key Risks for IVBT?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay drug development timelines.
- High volatility in the biotechnology sector impacting investor sentiment.
- Competition from larger, established pharmaceutical companies with more resources.
- Uncertainties surrounding the efficacy and safety of new drug formulations.
- Market risks related to the acceptance of psychedelic therapies.
What Threats Does IVBT Face?
- Regulatory hurdles in drug development and approval processes.
- Intense competition from both established and emerging biotech firms.
- Market risks associated with the volatility of the biotechnology sector.
What Are IVBT's Competitive Advantages?
- Unique focus on synthetic prodrugs derived from botanical sources.
- Specialization in under-researched therapeutic areas such as pediatric epilepsy and addiction.
- Strong potential for intellectual property protection through proprietary formulations.
- Ability to leverage emerging trends in mental health and cannabinoid therapies.
- Small, agile team allows for rapid decision-making and innovation.
What Does IVBT Do?
Founded in 2014, Innovation1 Biotech Inc., originally known as Gridiron BioNutrients, Inc., has established itself as a pioneering drug discovery enterprise based in Somerville, US. The company is dedicated to developing modified botanical Schedule 1 molecules, leveraging innovative approaches to create synthetic prodrugs aimed at treating a range of medical conditions. Currently, Innovation1 Biotech's pipeline includes five proprietary prodrugs in preclinical development, each targeting specific health issues. Among these, a notable psychedelic compound derived from mushrooms is designed to address post-traumatic stress disorder and depression, while another cannabinoid and tree bark-derived psychedelic aims to combat addiction. Additionally, the company is developing three cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. The firm’s commitment to addressing significant healthcare challenges positions it uniquely within the biotechnology sector, focusing on novel therapeutic solutions that are currently underrepresented in the market. With a small team of one employee, led by CEO Francis Knuettel, Innovation1 Biotech is poised to make strides in the healthcare landscape, particularly as it navigates the complexities of drug development and regulatory approval processes.
What Products and Services Does IVBT Offer?
- Develops modified botanical Schedule 1 molecules for medical use.
- Focuses on creating synthetic prodrugs targeting various medical conditions.
- Currently has five proprietary prodrugs in preclinical development.
- Targets mental health issues such as PTSD and depression.
- Aims to address pediatric epilepsy and other chronic conditions.
- Operates primarily within the United States healthcare market.
How Does IVBT Make Money?
- Revenue generation through the successful development and commercialization of proprietary prodrugs.
- Potential partnerships and collaborations with larger pharmaceutical firms for product development.
- Grants and funding opportunities aimed at supporting innovative drug research.
- Intellectual property licensing for proprietary drug formulations.
- Future revenue from sales of approved medications targeting unmet medical needs.
What Industry Does IVBT Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment, particularly in drug development targeting unmet medical needs. The global biotechnology market is projected to grow at a CAGR of approximately 7.4% from 2021 to 2028, driven by advancements in genetic research, personalized medicine, and the increasing prevalence of chronic diseases. Innovation1 Biotech Inc. is strategically positioned within this landscape, focusing on synthetic prodrugs that leverage botanical sources, an area that is gaining traction as regulatory frameworks evolve to accommodate novel therapeutic approaches. The competitive landscape includes a mix of established players and emerging firms, with Innovation1 Biotech's unique focus on psychedelic and cannabinoid therapies setting it apart.
Who Are IVBT's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from mental health issues and chronic conditions.
- Pharmaceutical companies interested in partnerships for drug development.
- Research institutions focused on drug discovery and development.
- Investors looking to support biotechnology innovations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Innovation1 Biotech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Innovation1 Biotech Inc. operates in the Financial Services sector. It is headquartered in New York, United States.
IVBT Latest News
No recent news available for IVBT.
IVBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IVBT.
Price Targets
Wall Street price target analysis for IVBT.
IVBT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IVBT; grades run from A+ (80-100) to F (below 30).
Leadership: Francis Knuettel
CEO
Francis Knuettel has been at the helm of Innovation1 Biotech Inc. since its inception in 2014. With a background in biotechnology and a passion for innovative healthcare solutions, he has guided the company through its early stages of development. His experience includes roles in research and development within the biotech sector, where he has cultivated a deep understanding of drug discovery processes and regulatory landscapes.
Track Record: Under Francis Knuettel's leadership, Innovation1 Biotech has transitioned from Gridiron BioNutrients, Inc. to its current focus on synthetic prodrugs. His strategic vision has positioned the company to explore novel therapeutic avenues, particularly in the fields of mental health and pediatric medicine.
IVBT OTC Market Information
The OTC Other tier includes companies that do not meet the financial or regulatory requirements for listing on major exchanges like NYSE or NASDAQ. This tier often features smaller, less liquid stocks, which can lead to higher volatility and trading costs compared to more established companies.
- OTC Tier: OTC Other
- Limited operational history and financial data due to its small size.
- Higher volatility associated with OTC stocks compared to those on major exchanges.
- Potential lack of investor interest leading to liquidity issues.
- Verify the company's financial health and funding status.
- Assess the progress of drug development and clinical trials.
- Confirm the legitimacy of the management team and their experience.
- Review any regulatory filings or disclosures made by the company.
- Investigate potential partnerships or collaborations in the pipeline.
- Established in 2014, indicating some operational history.
- Focus on innovative drug development in a growing market.
- Leadership with experience in biotechnology and drug discovery.
Innovation1 Biotech Inc. Financials Stock: Key Questions Answered
What are the main risks for IVBT?
Innovation1 Biotech Inc. faces several risks, including regulatory hurdles that could impact the timelines for drug development and approval. The company operates in a highly volatile biotechnology sector, where investor sentiment can fluctuate significantly.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Company operates in a high-risk sector with limited resources and operational history.